Pharvaris N.V. (PHVS)
NASDAQ: PHVS · IEX Real-Time Price · USD
20.35
-1.36 (-6.26%)
May 17, 2024, 4:30 PM EDT - Market closed
Pharvaris Employees
Pharvaris had 82 employees on December 31, 2023. The number of employees increased by 17 or 26.15% compared to the previous year.
Employees
82
Change (1Y)
17
Growth (1Y)
26.15%
Revenue / Employee
n/a
Profits / Employee
-$1,408,575
Market Cap
1.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 82 | 17 | 26.15% |
Dec 31, 2022 | 65 | 31 | 91.18% |
Dec 31, 2021 | 34 | 20 | 142.86% |
Dec 31, 2020 | 14 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Immatics | 535 |
Xencor | 280 |
Mirum Pharmaceuticals | 264 |
Prothena Corporation | 173 |
Scholar Rock Holding | 150 |
Verona Pharma | 79 |
Belite Bio | 20 |
PHVS News
- 5 days ago - Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses - GlobeNewsWire
- 9 days ago - Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference - GlobeNewsWire
- 2 months ago - Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses - GlobeNewsWire
- 2 months ago - Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses - GlobeNewsWire
- 2 months ago - Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 - GlobeNewsWire